Defining OGT's Essential Functions to Guide Therapeutic Approaches - EQUIPMENT SUPPLEMENT
Defining OGT's Essential Functions to Guide Therapeutic Approaches - EQUIPMENT SUPPLEMENT
批准号:
10386477
负责人:
Suzanne Walker
金额:
$7.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-02-01 至 2024-11-30
关键词:
AddressBindingBiochemistryBiologyCardiometabolic DiseaseCell NucleusCell SurvivalCellsComplications of Diabetes MellitusCytoplasmDrug TargetingFoundationsGenetic Predisposition to DiseaseGrowthHumanInsulin ResistanceKnowledgeLinkMalignant NeoplasmsMammalsMethodsO-GlcNAc transferasePathway interactionsPhenotypePhysiologicalPhysiologyProteinsProteomicsRoleScientific Advances and AccomplishmentsSupporting CellTechnologyTherapeuticVariantWorkcancer therapyconditional knockoutexperimental studyknock-downscaffoldsmall molecule inhibitortherapeutic targettool
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
O-GlcNAc transferase (OGT), an essential human protein, attaches N-acetylglucosamine (GlcNAc) to Ser/Thr
residues of proteins in the nucleus and cytoplasm. Dysregulated OGT expression and activity have been linked
to insulin resistance, diabetic complications, and cancer, making OGT a possible drug target. Developing
approaches to exploit OGT as a target requires understanding its physiological roles and the mechanisms by
which it achieves them. Studies to probe OGT’s physiological roles have relied heavily on knockdown (KD) or
conditional knockout (KO) experiments and the resulting phenotypes have been attributed to loss of O-GlcNAc.
However, OGT has a second catalytic activity and also binds cellular proteins that it does not glycosylate; some
phenotypes attributed to O-GlcNAc loss may therefore be due to loss of other activities. Previously, the
importance of OGT’s catalytic and noncatalytic functions could not be assessed because methods to replace
endogenous OGT with variants did not exist. We have now established methods to replace OGT and will analyze
cells containing specifically altered copies to deconvolute OGT’s physiological roles. Growth phenotypes,
quantitative proteomics, and biochemistry will be used to address several questions. Is OGT’s noncatalytic
scaffolding activity a major driver of physiology and what pathways are linked to it? What is the shortest OGT
construct that still supports cell survival and what proteins does it glycosylate and bind? How do OGT’s
substrates and binding partners interact with the TPR domain and are there opportunities to target specific
regions of this domain? We will also use a small molecule inhibitor we recently developed in a chemogenomics
screen to identify genetic vulnerabilities to loss of O-GlcNAc. In addition to advancing scientific knowledge about
one of the most fundamentally important proteins in mammalian biology, the work in this proposal will provide
the foundation to guide approaches to exploit OGT as a therapeutic target.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploiting membrane targets to overcome antibiotic resistance
-
批准号:10699952
-
项目类别:
-
资助金额:$251.52万
-
财政年份:2022
-
负责人:Suzanne Walker
-
依托单位:
Administrative Core
-
批准号:10699953
-
项目类别:
-
资助金额:$13.13万
-
财政年份:2022
-
负责人:Suzanne Walker
-
依托单位:
Project 2: Targeting Gram-positive Cell Envelope Assembly
-
批准号:10699955
-
项目类别:
-
资助金额:$73.23万
-
财政年份:2022
-
负责人:Suzanne Walker
-
依托单位:
Subproject 1 Compounds and Strategies for Treating MRSA and VRE
-
批准号:9151286
-
项目类别:
-
资助金额:$54.84万
-
财政年份:2016
-
负责人:Suzanne Walker
-
依托单位:
Enabling Biotechnologies to Generate Novel Phosphoglycolipid Antibiotics
-
批准号:8633483
-
项目类别:
-
资助金额:$3.88万
-
财政年份:2013
-
负责人:Suzanne Walker
-
依托单位:
Enabling Biotechnologies to Generate Novel Phosphoglycolipid Antibiotics
-
批准号:8411474
-
项目类别:
-
资助金额:$5.69万
-
财政年份:2013
-
负责人:Suzanne Walker
-
依托单位:
Enabling Biotechnologies to Generate Novel Phosphoglycolipid Antibiotics
-
批准号:8815348
-
项目类别:
-
资助金额:$3.88万
-
财政年份:2013
-
负责人:Suzanne Walker
-
依托单位:
Defining OGT's Essential Functions to Guide Therapeutic Approaches
-
批准号:10316265
-
项目类别:
-
资助金额:$44.31万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Structure, Function and Inhibition of Human O-GlcNAc Transferase
-
批准号:8234495
-
项目类别:
-
资助金额:$53.03万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Compound and Strategies for Treating MRSA and VRE
-
批准号:8376868
-
项目类别:
-
资助金额:$40.71万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Structure, Function and Inhibition of Human O-GlcNAc Transferase
-
批准号:9113808
-
项目类别:
-
资助金额:$42.94万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Structure, Function and Inhibition of Human O-GlcNAc Transferase
-
批准号:9025947
-
项目类别:
-
资助金额:$2.75万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Defining OGT's Essential Functions to Guide Therapeutic Approaches
-
批准号:10728402
-
项目类别:
-
资助金额:$7.77万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Defining OGT's Essential Functions to Guide Therapeutic Approaches
-
批准号:10524029
-
项目类别:
-
资助金额:$44.04万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Structure, Function and Inhibition of Human O-GlcNAc Transferase
-
批准号:8415976
-
项目类别:
-
资助金额:$49.87万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Structure, Function and Inhibition of Human O-GlcNAc Transferase
-
批准号:8796187
-
项目类别:
-
资助金额:$51.75万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Diversity Supplement: Defining OGT's Essential Functions to Guide Therapeutic Approaches
-
批准号:10472096
-
项目类别:
-
资助金额:$7.76万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Structure, Function and Inhibition of Human O-GlcNAc Transferase
-
批准号:9248380
-
项目类别:
-
资助金额:$42.94万
-
财政年份:2012
-
负责人:Suzanne Walker
-
依托单位:
Compound and Strategies for Treating MRSA and VRE
-
批准号:8202904
-
项目类别:
-
资助金额:$41.41万
-
财政年份:2011
-
负责人:Suzanne Walker
-
依托单位:
Harvard Chemical Biology Graduate Program
-
批准号:8287178
-
项目类别:
-
资助金额:$22.33万
-
财政年份:2011
-
负责人:Suzanne Walker
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: